Loading clinical trials...
Loading clinical trials...
A Phase 2 Randomized, Open-label Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With the Capsid Inhibitor Lenacapavir as Long-Acting Treatment Dosed Every 6 Months in Virologically Suppressed Adults With HIV-1 Infection
Conditions
Interventions
Teropavimab
Zinlirvimab
+3 more
Locations
34
United States
Ruane Clinical Research Group, Inc.
Los Angeles, California, United States
Mills Clinical Research
Los Angeles, California, United States
UC San Diego (UCSD) AntiViral Research Center (AVRC)
San Diego, California, United States
Optimus Medical Group
San Francisco, California, United States
University of Colorado Clinical and Translational Research Center
Aurora, Colorado, United States
Yale University; School of Medicine; AIDS Program
New Haven, Connecticut, United States
Start Date
May 15, 2023
Primary Completion Date
July 2, 2024
Completion Date
December 1, 2030
Last Updated
April 27, 2026
NCT06660498
NCT06602622
NCT06185452
NCT06902038
NCT04568603
NCT03001128
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions